Gurdeep Parmar, MBBS, MD, FRCPA, FRACP, discusses patient experience and preference findings from the phase 2 IZALCO study evaluating subcutaneous isatuximab administered via on-body injector in relapsed/refractory multiple myeloma.
Gurdeep Parmar, MBBS, MD, FRCPA, FRACP
Advertisement
Articles by Gurdeep Parmar, MBBS, MD, FRCPA, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5